- Home
- AIRT vs VRCA Comparison
AIRT vs VRCA Comparison
Compare AIRT & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- VRCA
- Stock Information
- Founded
- AIRT 1980
- VRCA 2013
- Country
- AIRT United States
- VRCA United States
- Employees
- AIRT N/A
- VRCA N/A
- Industry
- AIRT Air Freight/Delivery Services
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- VRCA Health Care
- Exchange
- AIRT Nasdaq
- VRCA Nasdaq
- Market Cap
- AIRT 53.2M
- VRCA 54.0M
- IPO Year
- AIRT N/A
- VRCA 2018
- Fundamental
- Price
- AIRT $22.48
- VRCA $0.56
- Analyst Decision
- AIRT
- VRCA Hold
- Analyst Count
- AIRT 0
- VRCA 5
- Target Price
- AIRT N/A
- VRCA $6.00
- AVG Volume (30 Days)
- AIRT 1.1K
- VRCA 427.9K
- Earning Date
- AIRT 06-27-2025
- VRCA 08-13-2025
- Dividend Yield
- AIRT N/A
- VRCA N/A
- EPS Growth
- AIRT N/A
- VRCA N/A
- EPS
- AIRT N/A
- VRCA N/A
- Revenue
- AIRT $291,850,000.00
- VRCA $7,179,000.00
- Revenue This Year
- AIRT N/A
- VRCA $171.87
- Revenue Next Year
- AIRT N/A
- VRCA $71.38
- P/E Ratio
- AIRT N/A
- VRCA N/A
- Revenue Growth
- AIRT 1.75
- VRCA N/A
- 52 Week Low
- AIRT $14.56
- VRCA $0.38
- 52 Week High
- AIRT $30.60
- VRCA $8.98
- Technical
- Relative Strength Index (RSI)
- AIRT 61.08
- VRCA 49.17
- Support Level
- AIRT $18.86
- VRCA $0.57
- Resistance Level
- AIRT $24.92
- VRCA $0.67
- Average True Range (ATR)
- AIRT 0.91
- VRCA 0.06
- MACD
- AIRT -0.03
- VRCA -0.01
- Stochastic Oscillator
- AIRT 65.92
- VRCA 14.73
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.